Clinical trial
Study of OT-551 Eye Drops to Prevent or Delay Progression of Nuclear Cataracts…
NCT00333060 · Othera Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00333060 |
|---|---|
| Title | Study of OT-551 Eye Drops to Prevent or Delay Progression of Nuclear Cataracts Following Vitreous Removal |
| Official title | Phase 2 Study of OT-551 Ophthalmic Solution to Prevent or Delay Progression of Nuclear Cataract Formation In Post-Vitrectomy Patients |
| Lead sponsor | Othera Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Epiretinal Membrane, Macular Hole |
| Intervention type | Drug |
| Interventions | OT-551 ophthalmic solution |
| Enrollment | 164 |
| Start date | Nov 1, 2005 |
| Completion | Jan 1, 2008 |
| First posted | Jun 2, 2006 |
| Last update posted | Apr 2, 2008 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: